Traws Pharma, Inc. annual report, FY2023

Filing and reporting period

Important identity discrepancy: The supplied filing is Onconova Therapeutics, Inc. (Nasdaq: ONTX), not Traws Pharma, Inc. It is an annual report for the fiscal year ended December 31, 2023; it does not provide standalone fourth-quarter results.

Business context

Onconova is a clinical-stage oncology biopharmaceutical company with two principal programs: narazaciclib, a multi-kinase inhibitor being studied in solid tumors and blood cancers, and rigosertib, studied alone or in combination. The company has no approved products and has generated no product-sales revenue.

Financial performance and liquidity

Revenue was entirely from recognition of the 2011 SymBio upfront license payment; no royalties or supply revenue were reported. R&D expense was essentially flat at $11.430 million. General and administrative expense rose 7.7% to $9.094 million, principally due to investor-relations, proxy, shareholder-meeting, professional-service and stock-compensation costs. Higher interest income helped keep net loss nearly unchanged despite increased operating expenses.

At year-end, cash and cash equivalents were $20.821 million, working capital was $13.4 million, total assets were $22.683 million, total liabilities were $12.011 million, and stockholders’ equity was $10.672 million. The balance sheet reports no borrowings; liabilities principally include accounts payable, accrued expenses and deferred revenue. Cash declined from $38.757 million at year-end 2022. The company estimated its cash would fund operations into the third quarter of 2024, but stated it lacked resources for the 12 months following issuance of the financial statements and disclosed substantial doubt about its ability to continue as a going concern.

Material changes and operating developments

• Operating cash use increased by $1.638 million year over year, while year-end cash fell by $17.936 million.
• Narazaciclib’s U.S. solid-tumor Phase 1 study was enrolling its seventh dose cohort; the sixth cohort had one dose-limiting toxicity. In a Phase 1/2a study with letrozole for recurrent or metastatic endometrial and other gynecologic cancers, the 160 mg cohort reported no dose-limiting toxicities; one was reported in the enrolling 200 mg cohort.
• Rigosertib studies included investigator-led trials in rare RDEB-associated squamous cell carcinoma and checkpoint-inhibitor-resistant cancers. Reported individual responses are preliminary and based on very small patient numbers. The KRAS-mutated NSCLC combination study had closed enrollment, with further studies pending a final report.
• Management expected 2024 net cash expenditures to exceed 2023 levels, citing narazaciclib trials and increased clinical and regulatory headcount; possible in-licensing could add costs.

Outlook, risks and unusual items

• Financing and going concern: Additional capital is required to fund trials and operations. Management planned to pursue equity and other financing, strategic alliances and business-development transactions, with no assurance of success. Failure to obtain funding could lead to reduced, delayed or discontinued development and operations. The independent auditor’s report includes a going-concern explanatory paragraph.
• Nasdaq listing: The company reported it had not regained the $1.00 minimum-bid-price requirement by March 25, 2024. Nasdaq granted a further compliance period through September 23, 2024; the company said it might use a reverse stock split. This is a post-year-end development disclosed in the filing.
• Development and execution risks: Clinical outcomes, regulatory approval, enrollment, manufacturing scale-up, reliance on third-party CROs and manufacturers, intellectual-property protection, competition and potential adverse effects remain significant uncertainties. The company also cited possible dilution or loss of product rights from future financing.
• Audit and controls: The financial statements received an unqualified audit opinion, alongside the going-concern emphasis. Clinical-trial expense accruals were identified as a critical audit matter due to estimates of vendor work completed. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-control attestation.

Key facts investors should verify

• Confirm the intended issuer: the filing is for Onconova Therapeutics, Inc. (ONTX), not Traws Pharma, Inc.
• Check subsequent financing, cash balance and actual runway against the stated third-quarter 2024 estimate, including any effect on the going-concern assessment.
• Review subsequent Nasdaq compliance status and whether a reverse stock split or other listing action occurred.
• Track updated narazaciclib dose-escalation and combination-trial safety, enrollment and efficacy data; do not treat preclinical findings as clinical proof.
• Assess final reports and further development decisions for rigosertib, noting that the highlighted RDEB-SCC responses involved very few patients.
• Review potential share dilution, outstanding options and warrants, and any financing or collaboration terms that could affect existing stockholders.